Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry

Genocea Biosciences (NASDAQ:GNCA) Earns Sell Rating From Analysts at StockNews.com

kopsource ·  {{timeTz}}

StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a report issued on Thursday morning. The brokerage issued a sell rating on the biotechnology company's stock.

Several other research firms also recently issued reports on GNCA. Stifel Nicolaus downgraded Genocea Biosciences from a buy rating to a hold rating in a report on Friday, April 29th. HC Wainwright downgraded Genocea Biosciences from a buy rating to a neutral rating in a report on Friday, April 29th.

Get Genocea Biosciences alerts:

Genocea Biosciences Price Performance

GNCA stock opened at $0.01 on Thursday. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.24. The company has a market capitalization of $640,200.60, a PE ratio of -0.02 and a beta of 2.00. Genocea Biosciences has a 12-month low of $0.01 and a 12-month high of $2.20. The business's fifty day moving average price is $0.01 and its 200 day moving average price is $0.42.

Institutional Investors Weigh In On Genocea Biosciences

A hedge fund recently bought a new stake in Genocea Biosciences stock. Acadian Asset Management LLC purchased a new position in shares of Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 21,741 shares of the biotechnology company's stock, valued at approximately $25,000. Institutional investors and hedge funds own 59.25% of the company's stock.

About Genocea Biosciences

(Get Rating)

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.

Featured Stories

  • Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
  • Why Trading Volume is Unusually High on These 3 Stocks
  • Can NetApp Resume Its Rally After Strong Earnings Guidance?
  • Three Reasons Why Medtronic Stock can be a Recession Winner
  • Rivian Rising to the Challenge
  • 3 Deflation Enablers Stocks that Can Thrive in a Recession

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.